PERK stress signaling shapes cancer-cell response to CDK4/6 inhibitors
Published in Diseases!, Drugs development & discovery, Journals.
Published October 18, 2026.
A study published in Nature Communications on October 17 identifies a stress-response pathway that may influence how cancer cells respond to CDK4/6 inhibitors, including palbociclib.
These drugs can initially put cells into a reversible resting state. The researchers investigated how cells subsequently commit to senescence, a more persistent growth arrest. They found that CDK4/6 inhibition activates PERK, a kinase involved in cellular responses to protein stress.
Blocking PERK alongside CDK4/6 accelerated senescence-associated changes. Separately, combining a CDK4/6 inhibitor with ISRIB, which inhibits the integrated stress response, suppressed tumor growth more effectively than either agent alone in the experimental systems studied. The authors linked this effect to increased senescence and immune surveillance.
Research significance: The findings suggest a combination-treatment strategy for cancers retaining a functional CDK4/6–RB1 pathway.
Limits: The report does not establish clinical benefit or safety in patients. Encouraging tumor cells to stop dividing is also distinct from eliminating senescent cells or reversing organismal aging. Further translational research is needed.
The available article is an early, peer-reviewed accepted version and remains subject to editorial changes.
Source: Farago and colleagues, Nature Communications, October 17, 2026.